Stephen H. Barnes Sells 5,640 Shares of Accolade, Inc. (NASDAQ:ACCD) Stock

Accolade, Inc. (NASDAQ:ACCD) CFO Stephen H. Barnes sold 5,640 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total transaction of $20,304.00. Following the completion of the sale, the chief financial officer now directly owns 219,623 shares in the company, valued at approximately $790,642.80. The trade was a 2.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Accolade Stock Up 4.2 %

Shares of NASDAQ ACCD opened at $3.69 on Friday. The company has a quick ratio of 2.72, a current ratio of 2.72 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $297.18 million, a PE ratio of -3.58 and a beta of 2.07. The firm has a fifty day moving average of $3.59 and a 200-day moving average of $4.34. Accolade, Inc. has a 52-week low of $3.08 and a 52-week high of $15.36.

Accolade (NASDAQ:ACCD) last released its quarterly earnings data on Tuesday, October 8th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. The company had revenue of $106.40 million for the quarter, compared to the consensus estimate of $104.87 million. Accolade had a negative return on equity of 18.43% and a negative net margin of 18.16%. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same period last year, the business posted ($0.43) EPS. On average, analysts anticipate that Accolade, Inc. will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ACCD. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Accolade in a research report on Monday, October 7th. Stephens lowered their target price on Accolade from $10.00 to $8.00 and set an “overweight” rating on the stock in a report on Wednesday, October 9th. Barclays cut their price target on Accolade from $5.50 to $5.00 and set an “equal weight” rating for the company in a report on Wednesday, October 9th. Canaccord Genuity Group decreased their price objective on Accolade from $13.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Truist Financial cut their target price on shares of Accolade from $9.00 to $7.50 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, Accolade currently has a consensus rating of “Moderate Buy” and an average target price of $9.04.

Institutional Investors Weigh In On Accolade

Large investors have recently made changes to their positions in the business. Mission Creek Capital Partners Inc. acquired a new stake in Accolade in the 3rd quarter valued at $38,000. SG Americas Securities LLC purchased a new stake in shares of Accolade during the 2nd quarter valued at about $43,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in Accolade during the 3rd quarter worth approximately $46,000. Wolverine Trading LLC purchased a new position in Accolade in the 3rd quarter worth approximately $51,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Accolade by 22.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,373 shares of the company’s stock valued at $73,000 after acquiring an additional 3,789 shares in the last quarter. Institutional investors and hedge funds own 84.99% of the company’s stock.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.